AGB+ Pressure Injectable Multi-Lumen CVC Kit The Arrow Central Venous Catheters are intended to permit venous access to the central circulation by way of the femoral, jugular or subclavian veins.The ARROWg+ard Blue® Catheter permits venous access to the central circulation by way of the femoral, jugular, or subclavian veins. The ARROWg+ard® technology is intended to provide protection against catheter-related bloodstream infections. It is not intended to be used as a treatment for existing infections nor is it indicated for long-term use (>30 days). The ARROWg+ard Blue PLUS® Multiple-Lumen Catheter permits venous access to the central circulation by way of the femoral, jugular, or subclavian veins. The ARROWg+ard® technology is intended to provide protection against catheter-related bloodstream infections (CRBSI). It is not intended to be used as a treatment for existing infections nor is it indicated for long-term use (>30 days). Clinical effectiveness of the ARROWg+ard Blue PLUS® catheter in preventing CRBSI's compared to the original ARROWg+ard Blue® catheter has not been studied
Publicado el 14 de junio de 2017 · Inicio del retiro: 20 de marzo de 2017
Resumen
FDA registra el retiro Z-2279-2017 de dispositivos médicos de Clase II, publicado el 14 de junio de 2017 e iniciado el 20 de marzo de 2017. Empresa responsable: Arrow International Inc; Estado: Finalizado; Cantidad reportada: N/A; Lote: Material number CDA-42703-P1A. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Arrow International initiated the recall due to reports of safety cover disengagement and needlestick injury for the BD Eclipse Needle that are packaged with certain Arrow products.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Arrow International Inc
- Distribuidor
- Nationwide Distribution
- Lote
- Material number CDA-42703-P1A
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAArrow AutoCAT2 Intra-Aortic Balloon Pump AUTOCAT2 WAVE JAPANESE, Product Code IAP-0500J8 de julio de 2020
- FDAArrow AC3 Optimus Intra-Aortic Balloon Pump AC3 Optimus IABP NA/AJLA, Product Code IAP-07018 de julio de 2020
- FDAArrow AutoCAT2 Intra-Aortic Balloon Pump AUTOCAT2 WAVE, Product Code IAP-05008 de julio de 2020
- FDAArrow AutoCAT2 Intra-Aortic Balloon Pump AUTOCAT 2, Product Code IAP-04008 de julio de 2020
- FDAAGB+ Pressure Injectable Multi-Lumen CVC Kit intended to permit venous access to the central circulation by14 de junio de 2017
- FDAArrow Pressure Injectable PICC Kit The Arrow International Pressure Injectable PICC is intended for short-term14 de junio de 2017
Preguntas sobre este retiro
¿AGB+ Pressure Injectable Multi-Lumen CVC Kit The Arrow Central Venous Catheters are intended to permit venous access to the central circulation by way of the femoral, jugular or subclavian veins.The ARROWg+ard Blue® Catheter permits venous access to the central circulation by way of the femoral, jugular, or subclavian veins. The ARROWg+ard® technology is intended to provide protection against catheter-related bloodstream infections. It is not intended to be used as a treatment for existing infections nor is it indicated for long-term use (>30 days). The ARROWg+ard Blue PLUS® Multiple-Lumen Catheter permits venous access to the central circulation by way of the femoral, jugular, or subclavian veins. The ARROWg+ard® technology is intended to provide protection against catheter-related bloodstream infections (CRBSI). It is not intended to be used as a treatment for existing infections nor is it indicated for long-term use (>30 days). Clinical effectiveness of the ARROWg+ard Blue PLUS® catheter in preventing CRBSI's compared to the original ARROWg+ard Blue® catheter has not been studied fue retirado del mercado?
Sí. FDA publicó el retiro Z-2279-2017 el 14 de junio de 2017. Peligro reportado: Arrow International initiated the recall due to reports of safety cover disengagement and needlestick injury for the BD Eclipse Needle that are packaged with certain Arrow products.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter